

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code : 1672)**

**CLARIFICATION ANNOUNCEMENT  
IN RELATION TO THE  
CHANGE OF COMPANY SECRETARY  
AND AUTHORISED REPRESENTATIVES**

Reference is made to the announcement of Ascletis Pharma Inc. (the “**Company**”) dated 22 August 2022 in relation to the change of company secretary and authorised representatives (the “**Announcement**”). Unless otherwise defined herein, capitalised terms shall have the same meanings ascribed to them in the Announcement.

The Company wishes to clarify that before and as at the date of this announcement, the authorised representatives of the Company under Rule 3.05 of the Listing Rules, namely Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu, remained unchanged. The Authorised Representatives as set out in the Announcement should be amended as “Authorised Representative” and its definition should be amended as follows:

“an authorised representative of the Company for accepting service of process or notice on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong).”

Save as disclosed above, all other information in the Announcement remains unchanged.

By order of the Board  
**Ascletis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People’s Republic of China  
August 24, 2022

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*